Cash Flow Statement

Currency: CAD

	Sep-2020	Dec-2020	Mar-2021	Jun-2021	Sep-2021	Dec-2021	Mar-2022	Jun-2022	Sep-2022	Dec-2022	Mar-2023	Jun-2023	Sep-2023	Dec-2023	Mar-2024
Operating Cash Flow
Net Income	(5)	(4)	(11)	(16)	(20)	(23)	(18)	(19)	(19)	(24)	(25)	(27)	(34)	(29)	(30)
Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	2	2	7	8	9	9	3	3	2	3	3	3	6	3	2
Change in Working Capital	1	2	(2)	(2)	(0)	(0)	1	3	(1)	2	1	0	2	5	7
Cash from Operating Activities	(1) N/A	(0) +70%	(5) -1 218%	(10) -80%	(11) -18%	(15) -31%	(14) +3%	(14) +4%	(17) -25%	(19) -10%	(21) -12%	(23) -9%	(25) -9%	(21) +18%	(21) +0%
Investing Cash Flow
Capital Expenditures	0	0	0	(0)	(0)	(0)	(0)	(1)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
Other Items	(0)	0	(5)	(5)	(5)	(14)	(9)	(18)	(18)	9	0	18	18	0	0
Cash from Investing Activities	(0) N/A	0 N/A	(5) N/A	(5) N/A	(5) -8%	(14) -166%	(9) +35%	(19) -97%	(18) +2%	9 N/A	9 N/A	18 +105%	18 +0%	(0) N/A	(0) +4%
Financing Cash Flow
Net Issuance of Common Stock	0	0	0	0	0	38	0	51	51	14	14	7	29	21	44
Net Issuance of Debt	1	(0)	3	12	12	12	10	0	(0)	(0)	(0)	(0)	(0)	(0)	(0)
Other	0	(0)	38	38	38	0	(38)	(38)	(38)	0	0	0	0	0	0
Cash from Financing Activities	1 N/A	(1) N/A	41 N/A	50 +23%	50 0%	50 +0%	9 -81%	13 +42%	13 -3%	14 +4%	14 +2%	7 -52%	29 +336%	21 -27%	44 +109%
Change in Cash
Effect of Foreign Exchange Rates	0	0	0	(0)	(0)	(0)	(0)	0	0	0	1	0	(0)	1	0
Net Change in Cash	(1) N/A	(1) -29%	31 N/A	35 +16%	33 -6%	21 -38%	(14) N/A	(19) -31%	(22) -17%	4 N/A	2 -49%	2 -15%	21 +1 174%	1 -95%	24 +2 081%
Free Cash Flow
Free Cash Flow	(1) N/A	(0) +70%	(5) -1 218%	(10) -81%	(12) -22%	(15) -30%	(15) +3%	(14) +2%	(17) -21%	(19) -10%	(21) -12%	(23) -9%	(25) -9%	(21) +18%	(21) +0%

Eupraxia Pharmaceuticals Inc
TSX:EPRX